Related Experiment Video
Updated: May 10, 2026

Isolation, Enrichment, and Maintenance of Medulloblastoma Stem Cells
Published on: September 1, 2010
Signaling pathway and molecular subgroups of medulloblastoma
Kay Ka-Wai Li1, Kin-Mang Lau, Ho-Keung Ng
1Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong, Hong Kong.
Abstract:
Medulloblastoma (MB) is the most common malignant brain tumor in children. Although multimodality treatment regimens including surgery, radiotherapy and chemotherapy have greatly improved disease outcome, about one-third of MB patient remains incurable, and many long-term survivors are suffered from deleterious effects due to aggressive treatment. Understanding the signaling pathways and the genetic mechanisms contributed to MB development would be the key to develop novel therapeutic treatment strategies for improving survival and outcome of MB. In this review, we discuss the biological signaling pathways involved in MB pathogenesis. We also go through the current international consensus of four core MB subgroups namely, SHH, WNT, Group 3, and Group 4. This is adopted based on the knowledge of genomic complexity of MB as analyzed by recent high-throughput genomic technology. We talk about immunohistochemistry assays established to determine molecular subgroup affiliation. In the last part of review, we discuss how identification of molecular subgroups is going to change our routine disease diagnosis and clinical management.
Insights
Medulloblastoma (MB), a common childhood brain tumor, requires better treatments. This review details MB signaling pathways and molecular subgroups (SHH, WNT, Group 3, Group 4) to guide improved diagnosis and therapy.
Area of Science:
- Pediatric Oncology
- Molecular Biology
- Genetics
Background:
- Medulloblastoma (MB) is the most common malignant pediatric brain tumor.
- Current treatments improve outcomes but leave many patients incurable and survivors with side effects.
- Understanding MB pathogenesis is crucial for developing novel therapeutic strategies.
Purpose of the Study:
- To review biological signaling pathways involved in medulloblastoma pathogenesis.
- To discuss the four core molecular subgroups of medulloblastoma: SHH, WNT, Group 3, and Group 4.
- To explore how molecular subgroup identification impacts diagnosis and clinical management.
Main Methods:
- Review of current literature on medulloblastoma signaling pathways and genetics.
- Analysis of high-throughput genomic data for medulloblastoma classification.
- Discussion of immunohistochemistry assays for molecular subgroup determination.
Main Results:
- Identification of key signaling pathways implicated in medulloblastoma development.
- Classification of medulloblastoma into four distinct molecular subgroups (SHH, WNT, Group 3, Group 4).
- Establishment of immunohistochemistry methods for reliable subgroup affiliation.
Conclusions:
- Understanding molecular subgroups is essential for advancing medulloblastoma treatment.
- Molecular subtyping promises to refine diagnosis and personalize clinical management strategies.
- Further research into signaling pathways and genetic mechanisms will drive therapeutic innovation for medulloblastoma.
Related Concept Videos
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Hedgehog Signaling Pathway
Hedgehog Signaling Pathway
Microtubules in Signaling
IP3/DAG Signaling Pathway
Notch Signaling Pathway
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not until 1985...
